Running interference: Scientists block viral RNA, aiming to cure hepatitis B by Carrie Bebermeyer, Saint Louis University edited by Stephanie Baum, reviewed by Andrew Zinin Editors' notes ...

In a recent paper published in Science Translational Medicine, scientists report that a class of drugs, called RNA interference (RNAi) therapeutics, represent a major advancement in the ...

China’s ruling Communist Party has told the country’s top judicial bodies to better research and understand international and foreign laws to fortify the nation’s legal arsenal against ...

Chart Industries Inc. (NYSE:GTLS) is one of the 10 most undervalued industrial stocks to buy according to analysts.

Chart Industries and Flowserve recently agreed to merge in an all-stock deal. The two companies outlined significant revenue and cost synergies. Strangely, both bargain-priced stocks fell after ...

U.S.-based equipment manufacturer Chart Industries and flow control systems maker Flowserve Corp agreed to merge in an all-stock deal, valuing the combined company at about $19 billion.

The molecular pathways involved in antiviral defenses and counter-defenses in host-pathogen systems remain unclear. Researchers have used Neurospora crassa as a model organism to explore how RNA ...

The chart is meant to help medical providers diagnose skin conditions and recommend treatment for airmen and Space Force guardians.

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.

After a pivotal study in the May 2001 issue of Nature showed that RNA could effectively silence gene expression in mammalian cell lines, RNA interference (RNAi) began to look like a possible contender ...

RNA interference – RNAi – functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking as a way to treat infections of bees by a commercially ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers.